In the News
Feb 01, 2011
Since Avastin’s 2008 FDA approval for breast cancer, IntrinsiQ data—which tracks use of all drugs for the treatment of cancer, both on- and off-label—have shown the lackluster penetration of Avastin within its indicated metastatic breast cancer market. This lack of use in the indicated market illustrates the fact that physicians do not rely solely on FDA approvals; and, in this case, the agency seemed to realize what most physicians already knew—Avastin was not providing value in the first-line setting for breast.
According to the IntrinsiQ data, physicians are more often using Avastin in breast cancer off-label. More importantly, this use is defensible given the extended time to progression the drug provides over non-Avastin therapy in the metastatic setting.